ADCT - ADC Therapeutics SA

1.1
-0.070   -6.364%

Share volume: 251,797
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$1.17
-0.07
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
31%
Profitability 0%
Dept financing 33%
Liquidity 75%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.78%
1 Month
-36.42%
3 Months
-41.49%
6 Months
-61.67%
1 Year
-76.99%
2 Year
-45.27%
Key data
Stock price
$1.10
P/E Ratio 
0.00
DAY RANGE
$1.10 - $1.22
EPS 
-$1.62
52 WEEK RANGE
$1.05 - $5.17
52 WEEK CHANGE
-$76.65
MARKET CAP 
192.412 M
YIELD 
N/A
SHARES OUTSTANDING 
96.647 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-05-2025
BETA 
1.73
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$472,541
AVERAGE 30 VOLUME 
$391,839
Company detail
CEO: Ameet Mallik
Region: US
Website: adctherapeutics.com
Employees: 310
IPO year: 2020
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

ADC Therapeutics SA develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial.

Recent news
loading